What is the size of the Plasmid DNA Manufacturing market in 2023?

The Plasmid DNA Manufacturing market size is USD 1185.7 Million in 2023.

What is the projected CAGR at which the Plasmid DNA Manufacturing market is expected to grow at?

The Plasmid DNA Manufacturing market is expected to grow at a CAGR of 21.8% (2024-2033).

List the segments encompassed in this report on the Plasmid DNA Manufacturing market?

Market.US has segmented the Plasmid DNA Manufacturing market by geographic (North America, Europe, APAC, South America, and Middle East and Africa). By Product the market has been segmented into Viral Vectors and Non-viral Vectors. By Grade the market has been segmented into R&D Grade, GMP Grade, and Clinical Grade), By Application the market has been segmented into DNA Vaccines, Cell & Gene Therapy, Immunotherapy, and Others. By Development Phase the market has been segmented into Pre-clinical Therapeutics, Clinical Therapeutics, and Marketed Therapeutics. By Disease the market has been segmented into Infectious Disease, Cancer, Genetic Disorder, and Others.

List the key industry players of the Plasmid DNA Manufacturing market?

VGXI, Inc., Akron Biotech, Cobra Biologics & Pharmaceutical Services, Aldevron, Plasmidfactory GmbH, Vigene Biosciences, Luminous Biosciences, Nature Technology Corporation, Delphi Genetics, BioNTech SE, KromaTiD, GenScript ProBio, and JAFRAL Ltd.

Which region is more appealing for vendors employed in the Plasmid DNA Manufacturing market?

North America is expected to account for the highest revenue share with 42.1%, and boasting an impressive market value of USD 499.2 Million. Therefore, the Plasmid DNA Manufacturing industry in North America is expected to garner significant business opportunities over the forecast period.

Name the key areas of business for Plasmid DNA Manufacturing?

The US, Canada, India, China, UK, Japan, & Germany are key areas of operation for the Plasmid DNA Manufacturing Market.

Plasmid DNA Manufacturing Market By Product (Viral Vectors and Non-viral Vectors), By Grade (R&D Grade, GMP Grade, and Clinical Grade), By Application (DNA Vaccines, Cell & Gene Therapy, Immunotherapy, and Others), By Development Phase (Pre-clinical Therapeutics, Clinical Therapeutics, and Marketed Therapeutics), By Disease (Infectious Disease, Cancer, Genetic Disorder, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: Aug 2024
Report ID: 127428
Number of Pages: 249
Format:

- VGXI, Inc.
- Akron Biotech
- Cobra Biologics & Pharmaceutical Services
- Aldevron
- Plasmidfactory GmbH
- Vigene Biosciences
- Luminous Biosciences
- Nature Technology Corporation
- Delphi Genetics
- BioNTech SE
- KromaTiD
- GenScript ProBio
- JAFRAL Ltd.
- Other Key Players
Settings

Related Reports

Our Clients

Inquiry Before Buying

Report ID 127428
Published Date Aug 2024
Rating
- ★★★★★
  
  ★★★★★
- (64)

Buy Now

Trusted by more than 17382 organizations globally

✖

Request a Sample Report

We'll get back to you as quickly as possible

	Single User $6,000 $3,999 USD / per unit save 24%	Multi User $8,000 $5,999 USD / per unit save 28%	Corporate User $10,000 $6,999 USD / per unit save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization	No	up to 10 hrs work	up to 30 hrs work
Accessibility	1 User	2-5 User	Unlimited
Analyst Support	up to 20 hrs	up to 40 hrs	up to 50 hrs
Benefit	Up to 20% off on next purchase	Up to 25% off on next purchase	Up to 30% off on next purchase
	Buy Now ($ 3,999)	Buy Now ($ 5,999)	Buy Now ($ 6,999)